Hayato Kawachi

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

Shunsuke Teraoka, Daichi Fujimoto, Takeshi Morimoto et al. · Journal of Thoracic Oncology · 2017 · 377 citations · Full text

Medicine, Immunology, Oncology +14

Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma

Hayato Kawachi, Kei Kunimasa, Yoji Kukita et al. · Immunotherapy · 2021 · 63 citations · Full text

Medicine, Oncology, Pharmacology +15

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Go Saito, Yuko Oya, Yoshihiko Taniguchi et al. · Lung Cancer · 2021 · 58 citations

Medicine, Oncology, Radiation Oncology +15

Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer

Daichi Fujimoto, Yuki Sato, Keiichiro Uehara et al. · Journal of Thoracic Oncology · 2017 · 57 citations

Medicine, Oncology, Cancer Immunology +14

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Medicine, Oncology, Pharmacology +17